A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs GSK 3359609 (Primary) ; Tremelimumab (Primary) ; Cetuximab; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 26 Oct 2019 Planned End Date changed from 16 Jun 2022 to 11 Sep 2023.
- 26 Oct 2019 Planned primary completion date changed from 16 Jun 2022 to 11 Sep 2023.
- 10 Jun 2019 Planned number of patients changed from 115 to 114.